Back to Journals » OncoTargets and Therapy » Volume 15

Chemotherapy Induces Ovarian Cancer Cell Repopulation Through the Caspase 3-Mediated Arachidonic Acid Metabolic Pathway [Corrigendum]

Authors Cui LZ, Zhao YW, Pan Y, Zheng X, Shao D , Jia Y, He K, Li K, Chen L

Received 15 November 2022

Accepted for publication 15 November 2022

Published 5 December 2022 Volume 2022:15 Pages 1503—1504

DOI https://doi.org/10.2147/OTT.S397709



Cui LZ, Zhao YW, Pan Y, et al. Onco Targets Ther. 2017;10:5817–5826.

The authors have advised that there is an error in Figure 5A on page 5823. During figure assembly, the Magnification 10x images for panels Control and PF562271 were switched in error.

The correct Figure 5 is as follows.

Figure 5 The influence of the FAK inhibitor PF562271 (PF) on the VP-16-induced repopulation of SKOV3 cells.

Abbreviations: FAK, focal adhesion kinase; VP-16, etoposide phosphate; SD, standard deviation.

Notes: (A) Representative images of the crystal violet staining assay of the receptor cells with the FAK inhibitor PF562271 (PF) added to the system. (B) The stained cells of the four groups in A were solubilized with 1 mL of 33% acetic acid and quantified by the absorbance at 570 nm. The results are expressed as the mean ± SD of three independent experiments, n=3, *P<0.05 compared with the control group, #P<0.05 compared with the model group.

The authors apologise for this error and advise it does not affect the results of the paper.


Read the original article


Creative Commons License © 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.